Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Opinion Off Script TCT 2019

Off Script: Want a Glimpse of Healthcare 3.0? Look Beyond Physician Burnout

Kwan S. Lee

September 27, 2019

News Opinion Off Script TCT 2017

Off Script: Focusing on the Future

Kwan S. Lee

October 31, 2017

Presentation TCT 2014

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Presenter: Fausto Feres

September 16, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

September 15, 2014

News Conference News TCT 2014

Novel Biodegradable Polymer DES Shows Efficacy, Long-term Safety

September 15, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

Presentation TCT 2013

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Presenter: Masato Nakamura

October 29, 2013

Presentation TCT 2013

The Evolution from Endeavor to Resolute: Stent Design Considerations and Results

Presenter: David Kandzari

October 28, 2013

News Conference News TCT 2012

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

October 24, 2012

Presentation TCT 2012

PROTECT: Three-Year Results of a Randomized Mega-Trial of Endeavor vs. Cypher

Presenter: Edoardo Camenzind

October 22, 2012

News Conference News TCT 2012

COURAGE, FAME: Revascularization More Effective Than OMT

October 22, 2012

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Conference News

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

November 08, 2011

News Conference News

ZES, EES Noninferior to PES

November 07, 2011

News Conference News

ZES Match or Exceed Performance of Earlier DES

November 07, 2011

Advertisement

Off Script: Want a Glimpse of Healthcare 3.0? Look Beyond Physician Burnout

Off Script: Focusing on the Future

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

Novel Biodegradable Polymer DES Shows Efficacy, Long-term Safety

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

OPTIMIZE: 3-Month DAPT Safe with ZES

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

The Evolution from Endeavor to Resolute: Stent Design Considerations and Results

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

PROTECT: Three-Year Results of a Randomized Mega-Trial of Endeavor vs. Cypher

COURAGE, FAME: Revascularization More Effective Than OMT

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

RAPID GENE: Validation of Point-of-Care Genetic Testing

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

ZES, EES Noninferior to PES

ZES Match or Exceed Performance of Earlier DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content